Caroline A Lee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10471883/publications.pdf

Version: 2024-02-01

24	4,219	471509 17	610901 24
papers	citations	h-index	g-index

25	25	25	5034
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Membrane transporters in drug development. Nature Reviews Drug Discovery, 2010, 9, 215-236.	46.4	2,886
2	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 4. Incorporation of P1 Lactam Moieties as l-Glutamine Replacements. Journal of Medicinal Chemistry, 1999, 42, 1213-1224.	6.4	175
3	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 6. Structureâ"Activity Studies of Orally Bioavailable, 2-Pyridone-Containing Peptidomimetics. Journal of Medicinal Chemistry, 2002, 45, 1607-1623.	6.4	137
4	Identification of Novel Substrates for Human Cytochrome P450 2J2. Drug Metabolism and Disposition, 2010, 38, 347-356.	3.3	120
5	Breast Cancer Resistance Protein (ABCG2) in Clinical Pharmacokinetics and Drug Interactions: Practical Recommendations for Clinical Victim and Perpetrator Drug-Drug Interaction Study Design. Drug Metabolism and Disposition, 2015, 43, 490-509.	3.3	116
6	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 8. Pharmacological Optimization of Orally Bioavailable 2-Pyridone-Containing Peptidomimetics. Journal of Medicinal Chemistry, 2003, 46, 4572-4585.	6.4	105
7	Structure-Based Design, Synthesis, and Biological Evaluation of Irreversible Human Rhinovirus 3C Protease Inhibitors. 1. Michael Acceptor Structureâ"Activity Studies. Journal of Medicinal Chemistry, 1998, 41, 2806-2818.	6.4	104
8	EVALUATION OF TIME-DEPENDENT INACTIVATION OF CYP3A IN CRYOPRESERVED HUMAN HEPATOCYTES. Drug Metabolism and Disposition, 2005, 33, 853-861.	3.3	80
9	Identifying a Selective Substrate and Inhibitor Pair for the Evaluation of CYP2J2 Activity. Drug Metabolism and Disposition, 2012, 40, 943-951.	3.3	78
10	P-glycoprotein related drug interactions: clinical importance and a consideration of disease states. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 603-619.	3.3	64
11	Digoxin Is Not a Substrate for Organic Anion-Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but Is a Substrate for a Sodium-Dependent Transporter Expressed in HEK293 Cells. Drug Metabolism and Disposition, 2011, 39, 2093-2102.	3.3	64
12	Refining the In Vitro and In Vivo Critical Parameters for P-Glycoprotein, [I]/IC50 and [I2]/IC50, That Allow for the Exclusion of Drug Candidates from Clinical Digoxin Interaction Studies. Molecular Pharmaceutics, 2010, 7, 398-411.	4.6	55
13	Transporter Expression in Noncancerous and Cancerous Liver Tissue from Donors with Hepatocellular Carcinoma and Chronic Hepatitis C Infection Quantified by LC-MS/MS Proteomics. Drug Metabolism and Disposition, 2018, 46, 189-196.	3.3	43
14	Application of Receiver Operating Characteristic Analysis to Refine the Prediction of Potential Digoxin Drug Interactions. Drug Metabolism and Disposition, 2013, 41, 1367-1374.	3.3	41
15	In Vitro Characterization of Axitinib Interactions with Human Efflux and Hepatic Uptake Transporters: Implications for Disposition and Drug Interactions. Drug Metabolism and Disposition, 2013, 41, 1575-1583.	3.3	40
16	Sequential Metabolism Is Responsible for Diltiazem-Induced Time-Dependent Loss of CYP3A. Drug Metabolism and Disposition, 2007, 35, 704-712.	3.3	37
17	Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers. Drug Design, Development and Therapy, 2016, Volume 10, 3555-3562.	4.3	24
18	Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 2683-2686.	2.2	18

#	Article	IF	Citations
19	Metabolism and Disposition of Verinurad, a Uric Acid Reabsorption Inhibitor, in Humans. Drug Metabolism and Disposition, 2018, 46, 532-541.	3.3	11
20	Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor. Clinical Drug Investigation, 2018, 38, 703-713.	2.2	7
21	Response from the International Transporter Consortium. Nature Reviews Drug Discovery, 2011, 10, 75-75.	46.4	5
22	Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers. Clinical Pharmacology in Drug Development, 2019, 8, 657-663.	1.6	3
23	Effects of Food and Antacids on Pharmacokinetics and Pharmacodynamics of Lesinurad, a Selective Urate Reabsorption Inhibitor. Clinical Pharmacology in Drug Development, 2019, 8, 647-656.	1.6	3
24	In Vitro Assessment of the Drugâ€“Drug Interaction Potential of Verinurad and Its Metabolites as Substrates and Inhibitors of Metabolizing Enzymes and Drug Transporters. Journal of Pharmacology and Experimental Therapeutics, 2021, 378, 108-123.	2.5	3